Study of exaptation evidence in clinical research for delivering pharmaceutical innovation
| Autor: | Milorad Stamenović |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Revizor. 24:7-16 |
| ISSN: | 2620-1461 1450-7005 |
| DOI: | 10.5937/rev2194007s |
| Popis: | Exaptation is a process that is characterized by the evolution of characteristics, its evolution for other usages, and later coopted for their current role. In the pharmaceutical industry, innovations have high potential in terms of competitive advantage and profit but are also connected with high risks associated with costs, time, and uncertainty. To minimize risks, companies frequently choose the strategy of exaptation in terms of redeveloping compounds for use in a different disease. The intention of this research is to provide analysis and quantification (measurement) of drugs that have been exaptated through the process of drug reposition. Results indicate that on level of 6098 clinical studies Phase I, we have observed a total of 659 drugs/substances (~11%) that have been used in more than one clinical research for the same or different indication showing the level of exaptation use in clinical research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|